BRAF Inhibitors Flashcards

1
Q

What drugs are in the BRAF Inhibitors class?

A

Drugs in this class are:
- Dabrafenib
- Vemurafenib
- Encorafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the brand name of Dabrafenib?

A

The brand name of this generic drug is:
- Tafinlar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the brand name of Vemurafenib?

A

The brand name of this generic drug is:
- Zelboraf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the brand name of Encorafenib?

A

The brand name of this generic drug is:
- Braftovi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the generic of name of Tafinlar?

A

The generic name of this brand name drug is:
- Dabrafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the generic of name of Zelboraf?

A

The generic name of this brand name drug is:
- Vemurafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the generic of name of Braftovi?

A

The generic name of this brand name drug is:
- Encorafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the main indications for use of Dabrafenib?

A

The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Non-small cell lung cancer (with BRAF V6ooE mutation)
- Thyroid cancer (with BRAF V6ooE mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the main indications for use of Vemurafenib?

A

The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Non-small cell lung cancer (with BRAF V6ooE mutation)
- Erdheim-Chester disease (with BRAF V6oo mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the main indications for use of Encorafenib?

A

The main indications of this drug are:
- Melanoma (with BRAFV6ooE or BRAFV6ooK mutation)
- Colorectal cancer (with BRAF V6ooE mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the class and MOA of Dabrafenib?

A

This drug in the following class:
- BRAF Inhibitors

This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the class and MOA of Vemurafenib?

A

This drug in the following class:
- BRAF Inhibitors

This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the class and MOA of Encorafenib?

A

This drug in the following class:
- BRAF Inhibitors

This drug’s MOA is as follows:
- Selectively targets mutated forms BRAF kinase (V600-) and interferes with the mitogen-activated protein kinase (MAPK) signaling pathway that regulates the proliferation and survival of melanoma cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the notable monitoring parameters for Vemurafenib?

A

The notable monitoring parameters for this drug are:
- See common parameters for class
- EKG at baseline. 15 days after initiation. then monthly for 3 months. then every 3 months thereafter (more frequently if clinically appropriate) and with dosage adjustments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the notable/common monitoring parameters for the BRAF Inhibitors class?

A

The notable/common monitoring parameters for this drug class are:
- BRAFV6ooK or V6ooE mutation status prior to treatment
- Dermatologic evaluations prior to initiation, every 2 months during therapy, and for up to 6 months following discontinuation to assess for new cutaneous malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the emetic potential of Dabrafenib?

A

The emetic potential of this drug is:
- Moderate - High

17
Q

What is the emetic potential of Vemurafenib?

A

The emetic potential of this drug is:
- Minimal - Low

18
Q

What is the emetic potential of Encorafenib?

A

The emetic potential of this drug is:
- Moderate - High

19
Q

Describe the emetic potential of the BRAF Inhibitors class.

A

The emetic potential of this drug class is:
- All moderate-high except for Vemurafenib (minimal-low)

20
Q

What drugs in the BRAF Inhibitors class have a moderate-high emetic potential?

A

Drugs in the class with a moderate-high emetic potential are:
- Dabrafenib
- Encorafenib

21
Q

What drugs in the BRAF Inhibitors class have a minimal-low emetic potential?

A

Drugs in the class with a minimal-low emetic potential are:
- Vemurafenib

22
Q

Describe the administration of Dabrafenib.

A

The administration of this drug is described as follows:
- Oral: Absorption decreased with a high fat meal (-1,000 calories: 58 to 75 grams of fat)

23
Q

Describe the administration of Vemurafenib.

A

The administration of this drug is described as follows:
- Oral

24
Q

Describe the administration of Encorafenib.

A

The administration of this drug is described as follows:
- Oral

25
Q

Describe the metabolism of Dabrafenib.

A

The metabolism of this drug is as follows:
- Patients with moderate (bilirubin >1,5 to 3 times ULN and any AST) or severe (bilirubin >3 to 10 times ULN and any AST) hepatic impairment may have increased exposure to this drug

26
Q

What are the notable ADRs of Vemurafenib?

A

The notable ADRs of this drug are:
- Secondary skin cancers
- QT prolongation

27
Q

What are the notable/common ADRs of the BRAF Inhibitors class?

A

The notable/common ADRs of this drug class are:
- Secondary skin cancers
- QT prolongation with Vemurafenib

28
Q

Describe the strategy and rationale for management of secondary skin cancers caused by BRAF inhibitors.

A

The strategy and rationale for management of this condition caused by this drug class are:
- Secondary cutaneous squamous cell cancers and keratoacanthomas are the result of compensatory RAF signaling seen with BRAF inhibition.
- The risk of these additional cancers is decreased with the addition of a MEK inhibitor.
- These cancers are typically localized and easily treated with surgical excision or topical fluorouracil cream.
- Regular skin assessments should be done throughout therapy with BRAF inhibitors.

29
Q

Describe the half-life of Encorafenib.

A

The half-life of this drug is described as follows:
- This drug has a longer dissociation half-life than other BRAF inhibitors, allowing for sustained inhibition of BRAF (and thus tumor growth)

30
Q

What are the clinical pearls of the BRAF Inhibitors class?

A

The clinical pearls of this drug class are as follows:
- Though the BRAF inhibitors were initially evaluated as single agents, combination therapy with a MEK inhibitor (ex: Trametinib) is now the recommended treatment regimen.

31
Q

Describe the therapy selection process for BRAF Inhibitors?

A

The therapy selection process for this drug class is as follows:
- All metastatic tumors should be evaluated for the V6oo mutation.
- In V6ooE or V6ooK mutated tumors, the initial selection between BRAF inhibitors and immunotherapy is commonly done based on the aggressive nature of the tumor.
- Rapidly growing tumors that are symptomatic are treated with BRAF-directed therapy because it generates a higher rate of response that occurs quicker, while asymptomatic or more indolent tumors may be treated with immunotherapy.

32
Q

Describe resistance among BRAF Inhibitors?

A

Resistance to this drug class is as follows:
- Though the BRAF inhibitors were initially evaluated as single agents, combination therapy with a MEK inhibitor (example: Trametinib) is now the recommended treatment regimen.
- This is due to the development of resistance to the single agent BRAF inhibitors after 6-7 months
- Combination therapy with both BRAF and MEK inhibitors may suppress the downstream resistance mechanism

33
Q

Describe the symptoms of melanoma.

A

Symptoms of this condition are:
- ABCDE: asymmetry, border, color, diameter, and evolving
- A: Asymmetry - melanomas are often asymmetrical
- B: Border - melanomas often have an irregular border
- C: Color - melanomas often have more than one color or shade in the mole
- D: Diameter: melanomas are often larger than 6mm, or the size of a pencil eraser
- E: Evolving: melanomas tend to change over time while benign moles do not